June 14, 2022 11:53 AM EDTUpdated 01:37 PM
Pharma
Marketing

Mar­ket­ingRx roundup: Pfiz­er keeps spot­light on JAKs with Cib­in­qo TV ad; Dex­com amps di­a­betes aware­ness in UK ef­fort

Beth Snyder Bulik

Senior Editor

Pfiz­er de­buted its first TV com­mer­cial for Cib­in­qo, its next-gen oral JAK in­hibitor to treat eczema, with a splashy spe­cial ef­fects spot about the new …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times